Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T23:41:50.000Z thumbnail image
  3. Check
    23 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the removal of detailed eligibility criteria and study objectives for a clinical trial on pembrolizumab for head and neck squamous cell carcinoma, while retaining the study's title and collaborator information.
    Difference
    50%
    Check dated 2025-04-16T14:48:30.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T10:32:19.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:41:30.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page has removed references to the Yale School of Medicine while adding Yale University, indicating a shift in focus from a specific institution to a broader one.
    Difference
    0.1%
    Check dated 2025-03-18T09:55:04.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T21:26:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.